CRISPR-Cas: Revolutionizing Detection and Treatment of Infectious Diseases

What is it about?

This article is a systematic review exploring the applications of the CRISPR-Cas system in the detection and treatment of infectious diseases. It highlights the evolution of CRISPR from a bacterial immune mechanism to a robust tool for genome editing, particularly in diagnosing diseases like COVID-19 through platforms such as SHERLOCK and DETECTR. The review underscores the therapeutic potential of CRISPR in editing viral genomes, notably hepatitis B virus and HIV, and its role in combating antibiotic resistance. The study discusses the promising outcomes from preclinical and clinical research, while acknowledging challenges such as off-target effects, immune responses, and delivery limitations. Ethical considerations and regulatory frameworks are emphasized, highlighting the importance of responsible implementation. Furthermore, the integration of nanotechnology and AI is suggested to enhance CRISPR's effectiveness.

Featured Image

Why is it important?

This review examines the applications of CRISPR-Cas systems in the detection and treatment of infectious diseases, highlighting their transformative potential in global health interventions. Given the increasing prevalence of infectious diseases and antimicrobial resistance, the synthesis of existing literature showcases how CRISPR technologies can offer precision and adaptability in both diagnostics and therapeutics, thus addressing critical gaps in current healthcare strategies. Key Takeaways: 1. This review article summarises the evolution of CRISPR-Cas systems from bacterial adaptive immunity mechanisms to powerful tools for precise genome editing, emphasizing their role in detecting and treating infectious diseases. 2. The review highlights the potential of CRISPR-based diagnostic platforms such as SHERLOCK and DETECTR, which have demonstrated high specificity and rapid detection capabilities, particularly during the COVID-19 pandemic. 3. It discusses the challenges and ethical considerations associated with CRISPR applications, such as off-target effects and immune responses, and underscores the importance of a robust regulatory framework and international collaboration for the responsible implementation of CRISPR technologies in healthcare.